For these studies, we obtained a novel murine PTEN−/− p53−/− prostate cancer cell line (P3CA) developed by Dr. Ming Chen (Duke University) that was derived from a genetic mouse prostate cancer model syngeneic on C57BL/6. This evidence concerns the gene TP53 and prostate carcinoma.